Bristol-Myers Squibb

BMY

Market cap $119B

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –

Autoimmune diseases, oncology, and type 2 diabetes continue to spread around the world, but these stocks stay off investors' radars. Many of them consistently beat Street's consensus forecasts and offer dividend yields even higher than oil and gas stocks, as well as the "Magnificent 7." By opening this article, you will find out my "top 4 Big Pharma players."

Values aren't always easy to find in the pharma sector. Bristol Myers Squibb has stable revenue, plus a strong dividend payout.

BMY stock jumps 10% in a month as growth drugs power revenues, but generic erosion and 2026 sales outlook keep investors cautious.

CVS Health and Bristol Myers Squibb are built to handle the toughest recessions. Both companies have maintained or increased their dividends through downturns over the past two decades.

BMY's Cobenfy gains traction with $155M in 2025 sales, outpacing peers and showing strong uptake as Bristol Myers eyes new indications and growth.

Oxford, UK and San Jose, California , 9 April 2026 – Oxford BioTherapeutics (“OBT”), is a clinical stage oncology company focused on the discovery and development of immuno-oncology (IO) and Antibody Drug Conjugate (ADC)-based therapies enabled by its OGAP®-Verify platform today announced a multi-year, selective target collaboration with Bristol Myers Squibb (NYSE: BMY, “BMS”) focussed on the discovery and development of novel T-cell engager therapies for solid tumours.

In the most recent trading session, Bristol Myers Squibb (BMY) closed at $59.2, indicating a +2.65% shift from the previous trading day.

The stock market's weakness might not be over — but it's not too early to start building a list of stocks to consider buying when investors are willing to take on more risk.

U.S. President Donald Trump's 100% tariffs on the pharmaceutical industry threaten global production, supply chains and ​ultimately will harm patients, Switzerland's pharmaceutical association interpharma said ‌on Friday.